Siemens Medical Solutions USA, Inc.

Westfaelische Wihelms-Universitaet Muenster

Andreas Faust

Michael Schaefers

Sven Hermann

Wei Zhang

Joseph C Walsh

Gang Chen

Umesh B Gangadharmath

Dhanalakshmi Kasi

Eric Wang

Anna Katrin Szardenings

Anjana Sinha

Chul Yu

Changhui Liu

Johannes Roth

Guenter Haufe

Thomas Vogl

Verena Hugenberg

Stefan Wagner

Hans-Joerg Breyholz

Harmuth C Kolb

Klaus Kopka

The present application provides quinoline-3-carboxamide compounds covalently linked to a label for use in the diagnosis of an inflammatory disease at local site. The above mentioned compounds can be used to detect or image accumulation of S100A9 in the body of a subject at sites of inflammation, using in vivo non-invasive molecular imaging techniques for the detection of said compounds. Accordingly, labeled quinoline-3-carboxamide compounds can be applied to evaluate the risk of a subject of developing an inflammatory disease and to follow the progress of the disease.

Quinoline-3-carboxamide compounds and their use in diagnosis

Novel compounds and pharmaceutical compositions having MMP inhibitory activity are disclosed, which have been found to be particularly useful in the prevention, treatment and diagnostic imaging of diseases associated with an unpaired activity of MMP, amongst others MMP-2, MMP-8, MMP-9 and/or MMP-13 to name a few. The compounds of the present invention are useful for the prevention, the treatment and the in vivo diagnostic imaging of a range of disease states (inflammatory, malignant and degenerative diseases) where specific matrix metalloproteinases are known to be involved.

Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof

Growing community of inventors

Billerbeck, Germany

Andreas Faust